What ACI LLP does

Asheesh Concentrates India Pvt. Ltd. (ACI) is a privately held Indian cannabis research, cultivation, and extraction company founded in 2018 and headquartered in Mumbai. It operates a vertically integrated supply chain — foraging, discovering, growing, harvesting, curing, and extracting indigenous Indian cannabis strains sourced from the Himalayan foothills — and holds what it describes as the only Indian license to cultivate and research indigenous cannabis strains (including high-THC varieties), granted through a 2019 narcotics-department approved R&D project conducted with the government-affiliated Central Institute of Medicinal and Aromatic Plants (CIMAP), where 15 scientists are dedicated to its program. The company's core products are medical-grade cannabis extract and indigenous cannabis strains, produced via a proprietary CO2-based "green" extraction technology that the company states uses no chemicals, solvents, or alcohols and is positioned as carbon-neutral; the technology is patented in Asia with rights acquired in 18 additional jurisdictions, and a library of over 150 cannabis genetics is being foraged, with three strains positioned as commercially ready (each under 0.3% THC), including a high-CBD strain for pain relief applications.

ACI's business model is B2B and partnership-driven. The company does not list a public price list, sells on a quote-based basis, and targets a broad set of business customers: pharmaceutical companies (for capsules, medical ointments, and medications), ayurvedic and alternative medicine practitioners, cosmetics companies, veterinary medicine suppliers, food suppliers, and hemp clothing, candle, incense, and fragrance producers. Distribution is currently domestic-India with stated international ambitions. Revenue mechanics rely on co-branding, licensing, and direct extract sales to these partners. There is no disclosed revenue, no disclosed funding rounds, and no publicly disclosed pricing. Notable backers include Pirojsha Godrej (Executive Chairman of Godrej Properties) as an investor/advisor, and the company cites an intent to become a global disruptor by introducing its strains and extracts internationally and establishing local extraction units abroad — though no commercial milestones toward that goal have been disclosed in the available sources.

Name

ACI LLP

Legal name

Asheesh Concentrates India Pvt. Ltd.

Website

https://asheeshconcentrates.com

Company type

Private

Founded year

2018

Operating status

Operating

Short description

Asheesh Concentrates India Pvt. Ltd. (ACI) is a privately held Indian cannabis research, cultivation, and extraction company that holds the only Indian license to study indigenous high-THC cannabis strains, operating a full forage-to-extract supply chain with proprietary CO2 technology and selling medical-grade extract to B2B partners across pharmaceuticals, ayurveda, cosmetics, and adjacent verticals.

Ownership category

akta.pro rank

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Cannabis Extract Sales: Sale of medical grade cannabis extract to pharmaceutical companies, cosmetics companies, and other B2B partners. Extract can be sold as-is or processed into capsules, medical ointments, medications, cosmetics, and other products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

ACI operates the complete supply chain of indigenous Indian cannabis (forage, discovery, grow, harvest, cure, extraction) and produces medical grade cannabis extract using proprietary patented CO2-based green extraction technology. The company supplies this extract, either as-is or processed into capsules, ointments, cosmetics, and medications, to B2B partners including pharmaceutical companies, ayurvedic/alternative medicine practitioners, cosmetics firms, veterinary medicine and food suppliers, and hemp/fragrance producers. ACI is the only entity in India licensed to cultivate and research indigenous cannabis strains (including high-THC varieties) via its research partnership with CIMAP.

Product overview

ACI LLP operates as a cannabis research, cultivation, and extraction company offering a complete supply chain from forage and discovery to extraction. The core product portfolio consists of medical grade cannabis extract and indigenous Indian cannabis strains. The company develops and owns proprietary green extraction technology to produce uniform, stable cannabinoid extracts. Three strains are ready for commercial launch, including a unique high CBD strain for pain relief applications. The company targets pharmaceutical companies, ayurvedic practitioners, cosmetics companies, veterinary medicine, and food suppliers with its extract products.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Grade Cannabis Extract Pure, organic cannabinoid extract formulated for medicinal purposes; uniform and stable in components and potency, produced using sustainable, green, non-toxic extraction technology compliant with FDA guidelines. Sold to B2B partners for use as-is or as an active ingredient in capsules, medical ointments, medications, cosmetics, and other products.
• Indigenous Indian Cannabis Strains Foraged cannabis genetics native to India and the Himalayan mountains, including over 150 different genetics being foraged with many indigenous strains discovered. Three strains are ready for commercial launch (each with less than 0.3% THC), developed under ACI's exclusive CIMAP research partnership. Intended for B2B partners and cultivation/processing licensees.
• High CBD Strain for Pain Relief A unique indigenous high-CBD cannabis strain developed for pain relief, also positioned as an anti-inflammatory and anti-depressant agent. Part of the commercially-ready indigenous strain portfolio launched under ACI's CIMAP research program.

Quantifiable outcome

• Over 150 cannabis genetics foraged, 3 strains ready for commercial launch
• +1 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• CIMAP (Central Institute of Medicinal and Aromatic Plants)coreStrategic or Co-development Partner · 1 January 2019ACI partnered with India's premier plant research laboratory CIMAP in 2019. CIMAP has dedicated a team of 15 scientists to ACI's cannabis research project titled 'Identification and Selection of THC, CBD, Cannabinoid Terpene THCa rich strains/lines/genotypes'. This is the only Cannabis related study sanctioned and granted licenses from all relevant Governmental authorities in India to legally grow Cannabis for research. CIMAP has multiple research facilities in various agro-climatic zones including Bangalore, Hyderabad, Pantnagar, Purara, and Lucknow (headquarters).

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Canopy Growth Corporation: Canadian licensed producer with global cannabis cultivation, extraction, and medical/pharmaceutical distribution — directly comparable to ACI in extract production targeting pharmaceutical and consumer health channels, though at vastly larger scale.
• Elixinol Wellness: Hemp-derived CBD extractor and B2B ingredient supplier with operations across multiple geographies; comparable to ACI's extract-to-B2B model and similar international expansion ambitions.
• CV Sciences: U.S. CBD extract manufacturer supplying pharmaceutical-grade cannabinoid ingredients to consumer brands — directly comparable to ACI's medical-grade extract sales to pharmaceutical and consumer product customers.
• Aurora Cannabis: Canadian licensed producer with medical cannabis extraction and international distribution operations; directly comparable as a vertically integrated cannabis cultivator-extractor with a medical-grade product focus.
• GW Pharmaceuticals (Jazz Pharmaceuticals): Developer of Epidiolex, the first FDA-approved plant-derived CBD pharmaceutical; directly comparable as a cannabis-extract-to-pharmaceutical company with patented botanical extraction IP — represents the archetype of the model ACI is pursuing.
• Medical Marijuana Inc (HempMeds): First U.S. company to pioneer CBD hemp oil distribution, with patent-protected cannabinoid extract products sold globally — directly comparable business model to ACI's hemp-extract B2B strategy.
• Charlotte's Web Holdings: Leading CBD hemp extract company selling standardized cannabinoid products to retail and B2B channels — comparable to ACI's hemp-extract segment under the <0.3% THC constraint, with established consumer brand and U.S. distribution.
• Tilray Brands: Global cannabis operator producing medical-grade cannabis extracts and supplying pharmaceutical and wellness markets in multiple jurisdictions — directly comparable B2B extract model with international footprint ACI aspires to build.

Broad incumbents

• Cronos Group: Diversified global cannabis company with cultivation, extraction, and consumer product lines; broader incumbent with overlapping cannabis-extract capabilities but also international brand investments outside ACI's current scope.

Emerging players

• Indiva: Canadian licensed cannabis producer focused on edible and extract products; smaller-scale emerging player similar in stage and resource constraints to ACI, providing a useful size-comparable benchmark.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ACI LLP